MaxCyte, Inc. (NASDAQ:MXCT) Director Sells $37,100.00 in Stock

MaxCyte, Inc. (NASDAQ:MXCT) Director John Joseph Johnston sold 10,000 shares of the business’s stock in a transaction on Tuesday, November 14th. The stock was sold at an average price of $3.71, for a total transaction of $37,100.00. Following the completion of the sale, the director now directly owns 120,583 shares of the company’s stock, valued at approximately $447,362.93. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

John Joseph Johnston also recently made the following trade(s):

• On Wednesday, August 30th, John Joseph Johnston sold 2,841 shares of MaxCyte stock. The shares were sold at an average price of $3.70, for a total transaction of $10,511.70.
• On Monday, August 28th, John Joseph Johnston sold 100 shares of MaxCyte stock. The stock was sold at an average price of $3.70, for a total transaction of $370.00.

MaxCyte Stock Up 4.3 %

Shares of MXCT opened at $3.90 on Friday. The firm’s fifty day moving average is $3.23 and its two-hundred day moving average is $3.95. MaxCyte, Inc. has a 52-week low of $2.45 and a 52-week high of $6.69.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on MXCT. William Blair reiterated an “outperform” rating on shares of MaxCyte in a report on Thursday, November 9th. Stephens restated an “overweight” rating and issued a $12.00 target price on shares of MaxCyte in a research report on Thursday, October 5th.

Hedge Funds Weigh In On MaxCyte

A number of institutional investors and hedge funds have recently bought and sold shares of MXCT. Harbor Capital Advisors Inc. purchased a new stake in MaxCyte in the 2nd quarter valued at $26,000. Quantbot Technologies LP purchased a new stake in MaxCyte in the second quarter valued at approximately $27,000. Victory Capital Management Inc. acquired a new position in MaxCyte during the 3rd quarter worth about $31,000. Johnson Investment Counsel Inc. purchased a new position in MaxCyte during the 3rd quarter valued at about $34,000. Finally, Tower Research Capital LLC TRC boosted its holdings in MaxCyte by 139.8% during the 1st quarter. Tower Research Capital LLC TRC now owns 7,108 shares of the company’s stock valued at $35,000 after acquiring an additional 4,144 shares during the period. 62.25% of the stock is currently owned by institutional investors and hedge funds.

MaxCyte Company Profile

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.